Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.46B |
| 2 |
NVIDIA
NVDA
|
+$1.08B |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$609M |
| 4 |
Moderna
MRNA
|
+$599M |
| 5 |
UBS Group
UBS
|
+$478M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.11B |
| 2 |
Apple
AAPL
|
+$679M |
| 3 |
Palo Alto Networks
PANW
|
+$450M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$428M |
| 5 |
Microsoft
MSFT
|
+$361M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.97% |
| 2 | Financials | 8.75% |
| 3 | Healthcare | 7.15% |
| 4 | Consumer Discretionary | 6.46% |
| 5 | Communication Services | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3501
Immunic
IMUX
$191M
| $217K | ﹤0.01% |
2,272
+1,507
| +197% | +$136K |
|
|
TRTN
3502
PUT
DELISTED
Triton International Limited
TRTN
| $217K | ﹤0.01% |
+3,600
| New | +$210K |
|
3503
EVI Industries
EVI
$188M
| $216K | ﹤0.01% |
6,935
+4,599
| +197% | +$147K |
|
3504
Flexsteel Industries
FLXS
$301M
| $213K | ﹤0.01% |
7,959
+5,244
| +193% | +$150K |
|
3505
PUT
Cheniere Energy
LNG
$54.1B
| $213K | ﹤0.01% |
2,100
-14,300
| -87% | -$1.49M |
|
3506
Citius Pharmaceuticals
CTXR
$17.4M
| $212K | ﹤0.01% |
5,513
+3,657
| +197% | +$166K |
|
3507
NN Inc
NNBR
$257M
| $212K | ﹤0.01% |
51,879
+34,412
| +197% | +$169K |
|
3508
CALL
Kratos Defense & Security Solutions
KTOS
$8.66B
| $211K | ﹤0.01% |
10,900
+8,300
| +319% | +$175K |
|
3509
CALL
Canadian Solar
CSIQ
$1B
| $210K | ﹤0.01% |
+6,700
| New | +$240K |
|
|
3510
PUT
Canadian Solar
CSIQ
$1B
| $210K | ﹤0.01% |
+6,700
| New | +$240K |
|
3511
Cytosorbents Corp
CTSO
$22M
| $210K | ﹤0.01% |
50,051
+32,885
| +192% | +$185K |
|
|
PZN
3512
DELISTED
Pzena Investment Management, Inc. Class A
PZN
| $210K | ﹤0.01% |
22,124
+15,220
| +220% | +$158K |
|
|
AXDX
3513
DELISTED
Accelerate Diagnostics
AXDX
| $209K | ﹤0.01% |
4,004
+2,656
| +197% | +$148K |
|
3514
PUT
Cooper Companies
COO
$14.2B
| $209K | ﹤0.01% |
+2,000
| New | +$204K |
|
3515
CorMedix
CRMD
$588M
| $209K | ﹤0.01% |
45,996
+30,509
| +197% | +$151K |
|
3516
Hamilton Beach Brands
HBB
$314M
| $209K | ﹤0.01% |
14,564
+5,978
| +70% | +$92K |
|
3517
Methanex
MEOH
$4.27B
| $209K | ﹤0.01% |
5,298
+4,492
| +557% | +$199K |
|
3518
LifeVantage
LFVN
$79.4M
| $207K | ﹤0.01% |
32,756
-1,709
| -5% | -$11.6K |
|
3519
Oil-Dri
ODC
$1.42B
| $207K | ﹤0.01% |
12,656
+8,394
| +197% | +$143K |
|
3520
XBiotech
XBIT
$68.3M
| $206K | ﹤0.01% |
18,484
+12,220
| +195% | +$159K |
|
|
ITI
3521
DELISTED
Iteris, Inc.
ITI
| $206K | ﹤0.01% |
51,411
+34,101
| +197% | +$165K |
|
|
ERUS
3522
DELISTED
iShares MSCI Russia ETF
ERUS
| $206K | ﹤0.01% |
4,802
+4,705
| +4,851% | +$223K |
|
3523
BeyondSpring
BYSI
$46.5M
| $204K | ﹤0.01% |
45,100
-128,098
| -74% | -$1.45M |
|
3524
Nathan's Famous
NATH
$403M
| $202K | ﹤0.01% |
3,453
+2,291
| +197% | +$140K |
|
3525
Silvercrest Asset Management
SAMG
$76.1M
| $202K | ﹤0.01% |
11,782
-1,447
| -11% | -$23.4K |
|
Similar funds
Barclays's Q4 2021 Portfolio in Review
As of Q4 2021, Barclays held 5,008 positions worth $268B, up 21% from $222B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Barclays deployed $30.5B of net new capital in Q4 2021, opening 209 new positions and adding to 2,223 existing holdings. Its largest new stake was UBS Group: 27,173,428 shares worth $486M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.11B trimmed.
- Barclays's largest Q4 2021 buy was UBS Group: 27,173,428 shares worth $486M.
- Barclays added most to iShares 20+ Year Treasury Bond ETF in Q4 2021, an estimated $1.46B increase.
- Barclays's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.11B.
- Barclays fully exited Vanguard Total International Bond ETF in Q4 2021, selling an estimated $89.8M.
- Barclays's ten largest holdings make up 30% of its $268B portfolio in Q4 2021.
- Barclays opened 209 new positions and closed 867 in Q4 2021.
- Barclays's portfolio value rose 21% quarter-over-quarter to $268B.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.